Breaking News Instant updates and real-time market news.

PEI

Pennsylvania REIT

$6.36 /

-0.46 (-6.74%)

06:57
08/18/22
08/18
06:57
08/18/22
06:57

PREIT announces additions to Cherry Hill Mall

PREIT announced additions to its flagship, Cherry Hill Mall. Joining recently-opened Warby Parker and Marc Cain, PREIT is pleased to share that first-to-portfolio leases have been executed with fashion brands - Psycho Bunny and Levi's for Cherry Hill Mall. Psycho Bunny, expected to open in mid-2023, is the brainchild of British fashion designer Robert Godley and American clothier Robert Goldman, both veterans in the menswear industry. The classic men's apparel brand prides itself on doing everything better than it's been done before and its logo. Levi's, expected to open this holiday season, will be the only full price store in the South Jersey market. As one of the world's largest apparel companies and a global leader in jeans, the brand has over 500 stores worldwide and products are available in more than 100 countries. The mall is also set to welcome one of two Rumi Life stores in the market. The mission of Rumi Life is to fill and satisfy all of life's desires, wants and needs at an affordable price. Eddie V's , a prime quality seafood restaurant, offering a fine dining experience, is expected to open its first South Jersey location and second in the state at the property in spring 2023. Even a 96.2% occupancy as of June 30, 2022, PREIT continues to generate interest from new retailers looking to expand in the market.

OTHER BREAKING NEWS FROM THE FLY

Conference/Events
Exxon Mobil to host conference call » 22:39
12/07/22
12/07
22:39
12/07/22
22:39
XOM

Exxon Mobil

$103.71 /

-0.14 (-0.13%)

Chairman & CEO Woods…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
XOM Exxon Mobil
$103.71 /

-0.14 (-0.13%)

XOM Exxon Mobil
$103.71 /

-0.14 (-0.13%)

11/22/22 Citi
Exxon Mobil price target raised to $110 from $98 at Citi
11/11/22 Piper Sandler
Exxon Mobil price target raised to $131 from $113 at Piper Sandler
11/01/22 Exane BNP Paribas
Exxon Mobil upgraded to Neutral from Underperform at Exane BNP Paribas
10/31/22 Truist
Exxon Mobil price target raised to $114 from $111 at Truist
XOM Exxon Mobil
$103.71 /

-0.14 (-0.13%)

XOM Exxon Mobil
$103.71 /

-0.14 (-0.13%)

XOM Exxon Mobil
$103.71 /

-0.14 (-0.13%)

XOM Exxon Mobil
$103.71 /

-0.14 (-0.13%)

Downgrade
Mirati Therapeutics downgraded to Market Perform from Outperform at BMO Capital » 21:27
12/07/22
12/07
21:27
12/07/22
21:27
MRTX

Mirati Therapeutics

$49.59 /

-22.03 (-30.76%)

BMO Capital analyst Evan…

BMO Capital analyst Evan Seigerman downgraded Mirati Therapeutics to Market Perform from Outperform with a price target of $59, down from $110. The analyst says that while adagrasib may have additive efficacy when combined with pembrolizumab, he sees a "long, expensive, and challenging path to Phase 3 data." Mirati is "likely dead money" until the Phase 3 data is released, which could be years, and the possibility for an acquisition is "likely off the table for now," Seigerman tells investors in a research note. He believes Mirati's path is "far from crystal clear."

ShowHide Related Items >><<
MRTX Mirati Therapeutics
$49.59 /

-22.03 (-30.76%)

MRTX Mirati Therapeutics
$49.59 /

-22.03 (-30.76%)

21:19 Today Piper Sandler
Mirati Therapeutics price target lowered to $84 from $110 at Piper Sandler
12/06/22 BofA
Mirati adagrasib plus PD1 combo efficacy below expectations, says BofA
12/02/22 Piper Sandler
Mirati trial continuation 'tilts the scale for a positive outcome,' says Piper
11/22/22 BMO Capital
BMO says Mirati could be valued at up to $200 per share in 'upside scenario'
MRTX Mirati Therapeutics
$49.59 /

-22.03 (-30.76%)

MRTX Mirati Therapeutics
$49.59 /

-22.03 (-30.76%)

MRTX Mirati Therapeutics
$49.59 /

-22.03 (-30.76%)

Recommendations
Mirati Therapeutics price target lowered to $84 from $110 at Piper Sandler » 21:19
12/07/22
12/07
21:19
12/07/22
21:19
MRTX

Mirati Therapeutics

$49.59 /

-22.03 (-30.76%)

Piper Sandler analyst…

Piper Sandler analyst Swapnil Malekar lowered the firm's price target on Mirati Therapeutics to $84 from $110 and keeps an Overweight rating on the shares. The company's investor event provided additional clarity on the response rates in patients broken down by TPS scores where data looks largely in line with the current standard of care, thus raising concerns on the applicability of ada+pembro combination in the front line setting, Malekar tells investors in a research note. However, the analyst says that given longer follow-up patients showed enhanced efficacy and a majority of patients continue to receive the combination therapy, he expects to see deepening of responses with longer treatment duration.

ShowHide Related Items >><<
MRTX Mirati Therapeutics
$49.59 /

-22.03 (-30.76%)

MRTX Mirati Therapeutics
$49.59 /

-22.03 (-30.76%)

12/06/22 BofA
Mirati adagrasib plus PD1 combo efficacy below expectations, says BofA
12/02/22 Piper Sandler
Mirati trial continuation 'tilts the scale for a positive outcome,' says Piper
11/22/22 BMO Capital
BMO says Mirati could be valued at up to $200 per share in 'upside scenario'
11/16/22 Citi
Mirati Therapeutics price target lowered to $121 from $127 at Citi
MRTX Mirati Therapeutics
$49.59 /

-22.03 (-30.76%)

MRTX Mirati Therapeutics
$49.59 /

-22.03 (-30.76%)

MRTX Mirati Therapeutics
$49.59 /

-22.03 (-30.76%)

Downgrade
Maple Leaf Foods downgraded to Market Perform from Outperform at BMO Capital » 21:02
12/07/22
12/07
21:02
12/07/22
21:02
MLFNF

Maple Leaf Foods

$17.92 /

-0.1489 (-0.82%)

BMO Capital analyst Peter…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
MLFNF Maple Leaf Foods
$17.92 /

-0.1489 (-0.82%)

10/31/22 Scotiabank
Maple Leaf Foods price target lowered to C$30 from C$34 at Scotiabank
08/05/22 TD Securities
Maple Leaf Foods price target lowered to C$39 from C$45 at TD Securities
08/05/22 Scotiabank
Maple Leaf Foods price target lowered to C$34 from C$40 at Scotiabank
07/19/22 Scotiabank
Maple Leaf Foods price target lowered to C$40 from C$42 at Scotiabank
Hot Stocks
Alpha & Omega announces executive leadership transition » 20:54
12/07/22
12/07
20:54
12/07/22
20:54
AOSL

Alpha & Omega

$32.21 /

+0.02 (+0.06%)

Alpha and Omega…

Alpha and Omega "announced that its board approved a leadership transition plan in which Dr. Mike Chang, currently Chief Executive Officer and Chairman of the Board, will serve as Executive Chairman of AOS, and he will transition the role of Chief Executive Officer to Mr. Stephen Chang, currently the President of AOS. The leadership transition will be effective on March 1, 2023. As a full-time Executive Chairman, Dr. Chang will continue to be deeply involved in AOS by focusing more on strategic matters such as key relationships with critical partners and customers of AOS and technology development essential to ensure sustained and long-term growth. Dr. Chang will also continue to serve as Chairman of the Board."

ShowHide Related Items >><<
AOSL Alpha & Omega
$32.21 /

+0.02 (+0.06%)

10/04/22 B. Riley
Alpha & Omega price target lowered to $38 from $45 at B. Riley
08/11/22 B. Riley
Alpha & Omega price target raised to $45 from $42 at B. Riley
08/11/22 Benchmark
Alpha & Omega price target lowered to $60 from $70 at Benchmark
06/15/22 B. Riley
B. Riley downgrades eight semi stocks on 'demand destruction risk'
AOSL Alpha & Omega
$32.21 /

+0.02 (+0.06%)

AOSL Alpha & Omega
$32.21 /

+0.02 (+0.06%)

Hot Stocks
Gilead's Kite Pharma, Daiichi Sankyo announce partnership revision » 20:04
12/07/22
12/07
20:04
12/07/22
20:04
GILD

Gilead

$87.80 /

-0.19 (-0.22%)

, DSNKY

Daiichi Sankyo

$31.93 /

+0.35 (+1.11%)

Kite Pharma, Inc., a…

Kite Pharma, Inc., a Gilead (GILD) Company and Daiichi Sankyo (DSNKY) "jointly announced the revision of their 2017 partnership agreement, which gave Daiichi Sankyo exclusive rights to develop, manufacture and commercialize Yescarta. axicabtagene ciloleucel, in Japan. Kite was acquired by Gilead Sciences, Inc. later in 2017 after the Daiichi Sankyo partnership agreement. Daiichi Sankyo and Kite have now agreed that the Marketing Authorization for Yescarta will be transferred to Gilead Sciences K.K., the Japan subsidiary of Gilead Sciences, Inc., in 2023. A Kite Cell Therapy Business Unit at Gilead Sciences K.K. will manage the sales and promotion activities of the product in Japan after the Marketing Authorization transfer. Kite's manufacturing facility in El Segundo, California, U.S., has been approved by Japanese regulatory authorities to manufacture Yescarta for the Japanese market, and it is expected that supply will commence in early 2023. The first axicabtagene ciloleucel treatment center in Japan was authorized in December 2021, and there are now six hospitals in Japan authorized to administer the therapy."

ShowHide Related Items >><<
GILD Gilead
$87.80 /

-0.19 (-0.22%)

DSNKY Daiichi Sankyo
$31.93 /

+0.35 (+1.11%)

GILD Gilead
$87.80 /

-0.19 (-0.22%)

12/05/22 RBC Capital
Gilead discontinuation 'curious,' but shouldn't derail cancer momentum, says RBC
12/01/22 Oppenheimer
Gilead price target raised to $105 from $95 at Oppenheimer
11/22/22 Guggenheim
MacroGenics upgraded to Buy at Guggenheim ahead of near-term catalysts
11/09/22 Argus
Gilead price target raised to $100 from $70 at Argus
DSNKY Daiichi Sankyo
$31.93 /

+0.35 (+1.11%)

11/01/22 CLSA
Daiichi Sankyo upgraded to Buy from Outperform at CLSA
08/14/22 Jefferies
Daiichi Sankyo upgraded to Buy from Hold at Jefferies
08/14/22 SVB Securities
Seagen price target lowered to $152 from $159 at SVB Securities
GILD Gilead
$87.80 /

-0.19 (-0.22%)

GILD Gilead
$87.80 /

-0.19 (-0.22%)

GILD Gilead
$87.80 /

-0.19 (-0.22%)

Hot Stocks
Cathie Wood's ARK Investment bought 106K shares of Verve Therapeutics today  20:02
12/07/22
12/07
20:02
12/07/22
20:02
VERV

Verve Therapeutics

$21.44 /

+0.36 (+1.71%)

 
ShowHide Related Items >><<
VERV Verve Therapeutics
$21.44 /

+0.36 (+1.71%)

VERV Verve Therapeutics
$21.44 /

+0.36 (+1.71%)

12/05/22 Stifel
Verve FDA request 'provides fodder for both bulls and bears,' says Stifel
12/02/22 Guggenheim
Beam hold being lifted 'encouraging' for Verve Therapeutics, says Guggenheim
10/06/22 Credit Suisse
Verve Therapeutics initiated with a Neutral at Credit Suisse
08/24/22 Stifel
Verve Therapeutics upgraded to Buy at Stifel on upside from near-term catalysts
VERV Verve Therapeutics
$21.44 /

+0.36 (+1.71%)

  • 21
    Jul
VERV Verve Therapeutics
$21.44 /

+0.36 (+1.71%)

Recommendations
Design Therapeutics' DT-216 phase 1 data looks promising, says Piper Sandler » 19:14
12/07/22
12/07
19:14
12/07/22
19:14
DSGN

Design Therapeutics

$12.69 /

-0.83 (-6.14%)

Piper Sandler analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
DSGN Design Therapeutics
$12.69 /

-0.83 (-6.14%)

DSGN Design Therapeutics
$12.69 /

-0.83 (-6.14%)

08/09/22 Wedbush
Design Therapeutics price target raised to $26 from $21 at Wedbush
06/10/22 Wedbush
Wedbush starts Design Therapeutics with an Outperform on lead asset optimism
06/09/22 Wedbush
Design Therapeutics initiated with an Outperform at Wedbush
05/02/22 RBC Capital
Design Therapeutics initiated with an Outperform at RBC Capital
DSGN Design Therapeutics
$12.69 /

-0.83 (-6.14%)

DSGN Design Therapeutics
$12.69 /

-0.83 (-6.14%)

Recommendations
CTS Eventim price target raised to EUR 77 from EUR 75 at Jefferies » 19:09
12/07/22
12/07
19:09
12/07/22
19:09
CEVMF

CTS Eventim

$44.00 /

+ (+0.00%)

Jefferies analyst Henrik…

Jefferies analyst Henrik Paganetty raised the firm's price target on CTS Eventim to EUR 77 from EUR 75 and keeps a Buy rating on the shares. The analyst said the firm's data suggests that pent-up demand for live events will continue in Q4, adding that he also believes the demand will continue due to the strong artist pipeline.

ShowHide Related Items >><<
CEVMF CTS Eventim
$44.00 /

+ (+0.00%)

11/25/22 DZ Bank
CTS Eventim upgraded to Buy from Hold at DZ Bank
11/23/22 Baader Helvea
CTS Eventim upgraded to Add from Reduce at Baader Helvea
11/22/22 Redburn
CTS Eventim AG initiated with a Buy at Redburn
On The Fly
Fly Intel: After-Hours Movers » 19:02
12/07/22
12/07
19:02
12/07/22
19:02
RENT

Rent The Runway

$1.35 /

-0.01 (-0.74%)

, HCP

HashiCorp

$26.64 /

+1.13 (+4.43%)

, GME

GameStop

$22.29 /

-1.12 (-4.78%)

, NAPA

Duckhorn Portfolio

$15.82 /

-0.09 (-0.57%)

, OXM

Oxford Industries

$108.20 /

-0.63 (-0.58%)

, ESEA

Euroseas

$19.30 /

-0.18 (-0.92%)

, GEF

Greif

$70.29 /

+0.05 (+0.07%)

, SPWH

Sportsman's Warehouse

$10.34 /

+0.3 (+2.99%)

, VRNT

Verint

$37.33 /

-0.14 (-0.37%)

, RLMD

Relmada Therapeutics

$4.16 /

-0.04 (-0.95%)

, DSGN

Design Therapeutics

$12.69 /

-0.83 (-6.14%)

, CHEF

Chefs' Warehouse

$37.23 /

-0.61 (-1.61%)

Check out this evening's…

ShowHide Related Items >><<
VRNT Verint
$37.33 /

-0.14 (-0.37%)

SPWH Sportsman's Warehouse
$10.34 /

+0.3 (+2.99%)

RLMD Relmada Therapeutics
$4.16 /

-0.04 (-0.95%)

RENT Rent The Runway
$1.35 /

-0.01 (-0.74%)

OXM Oxford Industries
$108.20 /

-0.63 (-0.58%)

NAPA Duckhorn Portfolio
$15.82 /

-0.09 (-0.57%)

HCP HashiCorp
$26.64 /

+1.13 (+4.43%)

GME GameStop
$22.29 /

-1.12 (-4.78%)

GEF Greif
$70.29 /

+0.05 (+0.07%)

DSGN Design Therapeutics
$12.69 /

-0.83 (-6.14%)

CHEF Chefs' Warehouse
$37.23 /

-0.61 (-1.61%)

RENT Rent The Runway
$1.35 /

-0.01 (-0.74%)

11/18/22 Morgan Stanley
Rent The Runway downgraded to Equal Weight from Overweight at Morgan Stanley
09/13/22 Morgan Stanley
Rent The Runway price target lowered to $13 from $14 at Morgan Stanley
09/13/22 JMP Securities
Rent The Runway price target lowered to $6 from $12 at JMP Securities
09/13/22 Barclays
Rent The Runway price target lowered to $6 from $7 at Barclays
HCP HashiCorp
$26.64 /

+1.13 (+4.43%)

10/06/22 Piper Sandler
HashiCorp price target raised to $39 from $38 at Piper Sandler
09/30/22 Truist
HashiCorp initiated with a Buy at Truist
09/30/22 Needham
Needham starts HashiCorp at Hold, says business model not in vogue as rates rise
09/30/22 Needham
HashiCorp initiated with a Hold at Needham
GME GameStop
$22.29 /

-1.12 (-4.78%)

10/13/22 Jefferies
GameStop transferred with a Hold at Jefferies
08/16/22 B. Riley
B. Riley downgrades 'meme stock' Bed Bath & Beyond to Sell
07/22/22 Wedbush
GameStop price target lowered to $7.50 from $30 at Wedbush
05/26/22 Wedbush
Wedbush keeps Underperform on GameStop citing valuation and cash burn concerns
NAPA Duckhorn Portfolio
$15.82 /

-0.09 (-0.57%)

10/10/22 Wedbush
Duckhorn Portfolio initiated with an Outperform at Wedbush
10/10/22 Wedbush
Duckhorn Portfolio initiated with an Outperform at Wedbush
10/03/22 Citi
Duckhorn Portfolio price target lowered to $18 from $20 at Citi
09/30/22 Barclays
Duckhorn Portfolio price target lowered to $18 from $19 at Barclays
OXM Oxford Industries
$108.20 /

-0.63 (-0.58%)

09/21/22 Citi
Oxford Industries upgraded to Neutral from Sell at Citi
09/20/22 CL King
Oxford Industries' acquisition of Johnny Was viewed positively, says CL King
09/20/22 Piper Sandler
Oxford Industries price target raised to $135 from $130 at Piper Sandler
08/23/22 Piper Sandler
Oxford Industries price target raised to $130 from $110 at Piper Sandler
ESEA Euroseas
$19.30 /

-0.18 (-0.92%)

11/17/22 Univest Securities
Euroseas price target lowered to $30 from $50 at Univest Securities
10/06/22 Maxim
Euroseas price target lowered to $44 from $54 at Maxim
05/19/22 Univest Securities
Euroseas initiated with a Buy at Univest Securities
12/31/21 Maxim
Euroseas price target raised to $50 from $48 at Maxim
GEF Greif
$70.29 /

+0.05 (+0.07%)

11/30/22 Wells Fargo
Greif price target raised to $69 from $63 at Wells Fargo
10/30/22 BMO Capital
Greif downgraded to Underperform from Market Perform at BMO Capital
10/13/22 BofA
BofA double downgrades Greif on recession risk into earnings
10/13/22 BofA
Greif downgraded to Underperform from Buy at BofA
SPWH Sportsman's Warehouse
$10.34 /

+0.3 (+2.99%)

09/26/22 B. Riley
Sportsman's Warehouse price target raised to $16 from $14 at B. Riley
09/23/22 Lake Street
Lake Street keeps Buy rating on Sportsman's Warehouse, 'encouraged' by targets
09/22/22 Baird
Sportsman's Warehouse FY25 targets imply EPS power of about $2, says Baird
09/02/22 Baird
Sportsman's Warehouse price target lowered to $9 from $11 at Baird
VRNT Verint
$37.33 /

-0.14 (-0.37%)

09/08/22 Wedbush
Verint price target lowered to $56 from $65 at Wedbush
09/08/22 RBC Capital
Verint price target lowered to $58 from $61 at RBC Capital
04/12/22 Goldman Sachs
Verint downgraded to Neutral from Buy at Goldman Sachs
03/30/22 RBC Capital
Verint price target raised to $61 from $57 at RBC Capital
RLMD Relmada Therapeutics
$4.16 /

-0.04 (-0.95%)

11/11/22 SVB Securities
Relmada 'still has a chance' for positive depression data, says SVB
10/14/22 BofA
Axsome shares could react positively to Relmada trial failure, says BofA
10/14/22 Goldman Sachs
Relmada Therapeutics downgraded to Neutral from Buy at Goldman Sachs
10/14/22 Truist
Relmada Therapeutics downgraded to Hold from Buy at Truist
DSGN Design Therapeutics
$12.69 /

-0.83 (-6.14%)

08/09/22 Wedbush
Design Therapeutics price target raised to $26 from $21 at Wedbush
06/10/22 Wedbush
Wedbush starts Design Therapeutics with an Outperform on lead asset optimism
06/09/22 Wedbush
Design Therapeutics initiated with an Outperform at Wedbush
05/02/22 RBC Capital
Design Therapeutics initiated with an Outperform at RBC Capital
CHEF Chefs' Warehouse
$37.23 /

-0.61 (-1.61%)

11/14/22 Benchmark
Chefs' Warehouse price target raised to $51 from $49 at Benchmark
09/14/22 CL King
Chefs' Warehouse currently best-positioned foodservice distributor, says CL King
08/22/22 BTIG
Chefs' Warehouse price target raised to $48 from $46 at BTIG
07/07/22 BMO Capital
Chefs' Warehouse price target raised to $48 from $44 at BMO Capital
VRNT Verint
$37.33 /

-0.14 (-0.37%)

SPWH Sportsman's Warehouse
$10.34 /

+0.3 (+2.99%)

RLMD Relmada Therapeutics
$4.16 /

-0.04 (-0.95%)

RENT Rent The Runway
$1.35 /

-0.01 (-0.74%)

OXM Oxford Industries
$108.20 /

-0.63 (-0.58%)

NAPA Duckhorn Portfolio
$15.82 /

-0.09 (-0.57%)

HCP HashiCorp
$26.64 /

+1.13 (+4.43%)

GME GameStop
$22.29 /

-1.12 (-4.78%)

GEF Greif
$70.29 /

+0.05 (+0.07%)

ESEA Euroseas
$19.30 /

-0.18 (-0.92%)

DSGN Design Therapeutics
$12.69 /

-0.83 (-6.14%)

CHEF Chefs' Warehouse
$37.23 /

-0.61 (-1.61%)

  • 07
    Jul
  • 09
    Dec
  • 09
    Dec
GME GameStop
$22.29 /

-1.12 (-4.78%)

VRNT Verint
$37.33 /

-0.14 (-0.37%)

SPWH Sportsman's Warehouse
$10.34 /

+0.3 (+2.99%)

RLMD Relmada Therapeutics
$4.16 /

-0.04 (-0.95%)

RENT Rent The Runway
$1.35 /

-0.01 (-0.74%)

OXM Oxford Industries
$108.20 /

-0.63 (-0.58%)

NAPA Duckhorn Portfolio
$15.82 /

-0.09 (-0.57%)

HCP HashiCorp
$26.64 /

+1.13 (+4.43%)

GME GameStop
$22.29 /

-1.12 (-4.78%)

GEF Greif
$70.29 /

+0.05 (+0.07%)

DSGN Design Therapeutics
$12.69 /

-0.83 (-6.14%)

CHEF Chefs' Warehouse
$37.23 /

-0.61 (-1.61%)

RLMD Relmada Therapeutics
$4.16 /

-0.04 (-0.95%)

RENT Rent The Runway
$1.35 /

-0.01 (-0.74%)

HCP HashiCorp
$26.64 /

+1.13 (+4.43%)

GME GameStop
$22.29 /

-1.12 (-4.78%)

Hot Stocks
NGM presents preliminary data from Phase 1 NGM707 trial » 18:46
12/07/22
12/07
18:46
12/07/22
18:46
NGM

NGM Biopharmaceuticals

$5.61 /

+0.09 (+1.63%)

NGM Biopharmaceuticals…

NGM Biopharmaceuticals announced the presentation of preliminary data from the Phase 1 Part 1a monotherapy dose escalation arm of the ongoing Phase 1/2 trial of NGM707 in patients with advanced or metastatic solid tumors at the European Society for Medical Oncology Immuno-Oncology (ESMO I-O) Annual Congress, which is taking place December 7 - 9, 2022 in Geneva, Switzerland. In the poster presentation titled, "First-in-Human Study of NGM707, an ILT2/ILT4 Dual Antagonist Antibody in Advanced or Metastatic Solid Tumors: Preliminary Monotherapy Dose Escalation Data" (#174P), NGM707 was generally well tolerated across all dose cohorts and demonstrated promising early signals of anti-tumor activity. Of 24 response-evaluable patients in the Part 1a arm, best overall responses as of November 23, 2022 are partial response in one patient, stable disease in six patients and non-complete response/non-progressive disease in one patient. Six patients had reduced target lesion size including a maximum decrease in one patient of 70%. "NGM707 is designed to reprogram immune-suppressive ILT4- and ILT2-expressing myeloid cells and ILT2-expressing lymphoid cells in the tumor microenvironment into immune-stimulatory cells that will promote anti-tumor activity. We're pleased to present these initial data demonstrating a favorable tolerability profile for NGM707 as well as early, yet promising signals that this mechanistic approach may translate to clinical benefit," said Dan Kaplan, Ph.D., Head of Translational Immuno-Oncology at NGM Bio. "We're particularly encouraged to see clinical benefit in certain patients in response to monotherapy treatment with NGM707, and we look forward to evaluating NGM707's potential effect when combined with T cell checkpoint inhibition in Part 1b of the study, which is now underway."

ShowHide Related Items >><<
NGM NGM Biopharmaceuticals
$5.61 /

+0.09 (+1.63%)

NGM NGM Biopharmaceuticals
$5.61 /

+0.09 (+1.63%)

10/18/22 Cowen
NGM Biopharmaceuticals price target lowered to $9 from $32 at Cowen
10/17/22 Raymond James
NGM Biopharmaceuticals cut at Raymond James, off ACF list after trial miss
10/17/22 Raymond James
NGM Biopharmaceuticals downgraded to Outperform from Strong Buy at Raymond James
10/17/22 Goldman Sachs
NGM Biopharmaceuticals downgraded to Neutral from Buy at Goldman Sachs
NGM NGM Biopharmaceuticals
$5.61 /

+0.09 (+1.63%)

NGM NGM Biopharmaceuticals
$5.61 /

+0.09 (+1.63%)

Hot Stocks
Campbell Soup CEO: The supply chain is now a 'real strength' » 18:46
12/07/22
12/07
18:46
12/07/22
18:46
CPB

Campbell Soup

$56.16 /

+3.175 (+5.99%)

In an interview on…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
CPB Campbell Soup
$56.16 /

+3.175 (+5.99%)

CPB Campbell Soup
$56.16 /

+3.175 (+5.99%)

11/15/22 Exane BNP Paribas
Campbell Soup initiated with an Underperform at Exane BNP Paribas
09/13/22 UBS
Campbell Soup's top-line guidance may be hard to achieve, says UBS
09/02/22 Piper Sandler
Campbell Soup price target lowered to $46 from $47 at Piper Sandler
08/25/22 JPMorgan
Campbell Soup price target raised to $49 from $46 at JPMorgan
CPB Campbell Soup
$56.16 /

+3.175 (+5.99%)

CPB Campbell Soup
$56.16 /

+3.175 (+5.99%)

CPB Campbell Soup
$56.16 /

+3.175 (+5.99%)

CPB Campbell Soup
$56.16 /

+3.175 (+5.99%)

Hot Stocks
Juniper CEO sells $604K in common stock » 18:36
12/07/22
12/07
18:36
12/07/22
18:36
JNPR

Juniper

$31.97 /

-0.17 (-0.53%)

In a regulatory filing,…

In a regulatory filing, Juniper disclosed that its CEO Rami Rahim sold 18,750 shares of common stock on December 5th in a total transaction size of $604K.

ShowHide Related Items >><<
JNPR Juniper
$31.97 /

-0.17 (-0.53%)

JNPR Juniper
$31.97 /

-0.17 (-0.53%)

10/26/22 Piper Sandler
Juniper price target raised to $31 from $29 at Piper Sandler
10/21/22 Raymond James
Juniper upgraded to Strong Buy from Outperform at Raymond James
10/21/22 Raymond James
Juniper upgraded to Strong Buy from Outperform at Raymond James
10/18/22 Piper Sandler
Juniper upgraded to Neutral from Underweight at Piper Sandler
JNPR Juniper
$31.97 /

-0.17 (-0.53%)

JNPR Juniper
$31.97 /

-0.17 (-0.53%)

JNPR Juniper
$31.97 /

-0.17 (-0.53%)

JNPR Juniper
$31.97 /

-0.17 (-0.53%)

Hot Stocks
Norfolk Southern CEO: We're focused on service » 18:24
12/07/22
12/07
18:24
12/07/22
18:24
NSC

Norfolk Southern

$241.59 /

-0.81 (-0.33%)

In an interview on…

In an interview on CNBC's Mad Money, Alan Shaw said, "Our focus on service is a competitive advantage." The company is targeting the trucking and logistics market, he noted. Shaw is seeing a trend towards onshoring amid geopolitical and energy risk, and is "really confident" about Norfolk Southern's future.

ShowHide Related Items >><<
NSC Norfolk Southern
$241.59 /

-0.81 (-0.33%)

NSC Norfolk Southern
$241.59 /

-0.81 (-0.33%)

12/05/22 Barclays
Norfolk Southern price target raised to $255 from $240 at Barclays
12/01/22 Wells Fargo
Norfolk Southern price target raised to $285 from $260 at Wells Fargo
11/29/22 Citi
Norfolk Southern price target raised to $250 from $225 at Citi
11/28/22 Deutsche Bank
Norfolk Southern price target raised to $273 from $220 at Deutsche Bank
NSC Norfolk Southern
$241.59 /

-0.81 (-0.33%)

NSC Norfolk Southern
$241.59 /

-0.81 (-0.33%)

NSC Norfolk Southern
$241.59 /

-0.81 (-0.33%)

Hot Stocks
G1 Therapeutics reports Phase 2 results of trilaciclib in breast cancer » 18:09
12/07/22
12/07
18:09
12/07/22
18:09
GTHX

G1 Therapeutics

$6.36 /

+0.02 (+0.32%)

G1 Therapeutics provided…

G1 Therapeutics provided initial results from a 24 patient Phase 2 mechanism of action - MOA - trial showing favorable alterations in the tumor microenvironment from a single dose of trilaciclib monotherapy as measured by increases in the proportions of CD8+ T cells compared to T regulatory cells in patients with early-stage triple negative breast cancer - TNBC -. CMO Raj Malik said, "These are the first data to show the beneficial effect of a single dose of trilaciclib, one week after administration, on the tumor microenvironment. These results show that trilaciclib monotherapy can improve the ratio of CD8+ T cells to Tregs and thus may enhance the overall antitumor immune response and confirm the trends we observed in preclinical studies and in peripheral blood in our Phase 2 trial in TNBC. We look forward to the pathologic complete response data in 2Q23 which we believe will clarify the ability of trilaciclib to improve anti-tumor efficacy for TNBC patients in this early-stage treatment setting, particularly in combination with a checkpoint inhibitor." Initial safety and tolerability results from the treatment phase are consistent with historical safety data from the standard of care neoadjuvant regimen with potential observed reductions in certain hematologic adverse events. There were no instances of grade 3/4 diarrhea in patients receiving trilaciclib in this trial. The new Phase 2 MOA initial clinical results reinforce those from two nonclinical studies presented at SITC, which showed that trilaciclib upregulates key processes within the cancer immunity cycle. Both the clinical and nonclinical data elucidate the immunologic mechanisms underlying the significant survival benefit shown in the previous Phase 2 trial of metastatic triple negative breast cancer patients who received trilaciclib prior to gemcitabine/carboplatin. Additionally, the combined data sets offer proof of principle data that trilaciclib may confer multidimensional clinical benefits across different tumor types and classes of drug.

ShowHide Related Items >><<
GTHX G1 Therapeutics
$6.36 /

+0.02 (+0.32%)

GTHX G1 Therapeutics
$6.36 /

+0.02 (+0.32%)

11/23/22 H.C. Wainwright
G1 Therapeutics price target lowered to $34 from $57 at H.C. Wainwright
11/02/22 H.C. Wainwright
G1 Therapeutics price target lowered to $57 from $67 at H.C. Wainwright
09/16/22 Wedbush
G1 Therapeutics price target raised to $25 from $20 at Wedbush
GTHX G1 Therapeutics
$6.36 /

+0.02 (+0.32%)

  • 18
    Nov
GTHX G1 Therapeutics
$6.36 /

+0.02 (+0.32%)

Hot Stocks
Puma Biotechnology presents updated findings from TBCRC-022 trial » 18:04
12/07/22
12/07
18:04
12/07/22
18:04
PBYI

Puma Biotechnology

$4.17 /

-0.16 (-3.70%)

Puma Biotechnology…

Puma Biotechnology presented updated findings from the Translational Breast Cancer Research Consortium Trial 022 at the ongoing 2022 San Antonio Breast Cancer Symposium in San Antonio, Texas. The poster, entitled "Neratinib and ado-Trastuzumab-Emtansine for HER2+ Breast Cancer Brain Metastases: Translational Breast Cancer Research Consortium Trial 022," was presented by Rachel A Freedman, MD, MPH, Breast Oncology Center, Susan F. Smith Center for Women's Cancers, Dana Farber Cancer Institute, at Spotlight Poster Session 7 on December 7 from 5:00 p.m. - 6:15 p.m. CT. TBCRC-022 is a prospective, multicenter, Phase II study to evaluate the effect of neratinib plus T-DM1 in patients with HER2-positive breast cancer brain metastases. This presentation outlined updates from three cohorts: 4A - patients with previously untreated BCBM; 4B - patients with BCBM progressing after prior local CNS-directed therapy without prior T-DM1 exposure; and 4C - patients with BCBM progressing after prior local CNS-directed therapy with previous T-DM1 exposure. Data from previous cohorts from this study were reported at the 2017 ASCO Annual Meeting. Patients with measurable HER2-positive BCBM received neratinib 160 mg orally once daily plus T-DM1 3.6 mg/kg intravenously every 21 days in the three parallel-enrolling cohorts. Diarrhea prophylaxis with colestipol and loperamide was required during cycle 1. All enrolled patients underwent a brain MRI plus CT scan of the chest/abdomen/pelvis every 6 weeks for 18 weeks, followed by every 9 weeks thereafter. The primary endpoint, Response Assessment in Neuro-Oncology-Brain Metastases, was evaluated in each cohort separately. The efficacy results from the trial showed that CNS Objective Response Rate by RANO-BM was 33.3% of patients in cohort 4A, 29.4% in cohort 4B, and 28.6% in cohort 4C. Rates of response + stable disease greater than or equal to 6 months were 50% in cohort 4A, 35.3% in cohort 4B, and 33.3% in cohort 4C. Intracranial activity was observed for the combination of neratinib plus T-DM1 in all three cohorts, including in patients with prior T-DM1 exposure, suggesting a reversal of resistance to T-DM1. Overall, the most frequently observed adverse event was diarrhea, grade 2 (32%) and grade 3 (23%). These data provide additional evidence for the consideration of neratinib-based combinations in patients with HER2-positive BCBM.

ShowHide Related Items >><<
PBYI Puma Biotechnology
$4.17 /

-0.16 (-3.70%)

PBYI Puma Biotechnology
$4.17 /

-0.16 (-3.70%)

08/05/22 H.C. Wainwright
Puma Biotechnology price target lowered to $8 from $12 at H.C. Wainwright
05/06/22 H.C. Wainwright
Puma Biotechnology price target lowered to $12 from $14 at H.C. Wainwright
PBYI Puma Biotechnology
$4.17 /

-0.16 (-3.70%)

PBYI Puma Biotechnology
$4.17 /

-0.16 (-3.70%)

Recommendations
Lowe's price target raised to $246 from $241 at Goldman Sachs » 17:51
12/07/22
12/07
17:51
12/07/22
17:51
LOW

Lowe's

$206.94 /

+4.87 (+2.41%)

, HD

Home Depot

$320.13 /

+2.55 (+0.80%)

Goldman Sachs analyst…

Goldman Sachs analyst Kate McShane raised the firm's price target on Lowe's (LOW) to $246 from $241 and keeps a Buy rating on the shares. The analyst states that she is incrementally more positive about the company after its Analyst Day given that the management believes their weak market scenario is the least likely outcome for 2023. McShane further notes that Lowe's FY23 guidance contemplates above-consensus operating margin, while its long-term EBIT margin target of 14.5% would put the company much closer to Home Depot's (HD) levels.

ShowHide Related Items >><<
LOW Lowe's
$206.94 /

+4.87 (+2.41%)

HD Home Depot
$320.13 /

+2.55 (+0.80%)

LOW Lowe's
$206.94 /

+4.87 (+2.41%)

15:38 Today Baird
Baird remains 'opportunistic buyer' of Lowe's after investor meeting
12/06/22 Bernstein
Lowe's initiated with a Market Perform at Bernstein
11/17/22 Telsey Advisory
Lowe's price target raised to $255 from $250 at Telsey Advisory
11/17/22 Truist
Target price target lowered to $151 from $165 at Truist
HD Home Depot
$320.13 /

+2.55 (+0.80%)

12/06/22 Bernstein
Home Depot initiated with a Market Perform at Bernstein
11/16/22 Wells Fargo
Lowe's 'gives bull case a boost' in Q3, says Wells Fargo
LOW Lowe's
$206.94 /

+4.87 (+2.41%)

HD Home Depot
$320.13 /

+2.55 (+0.80%)

LOW Lowe's
$206.94 /

+4.87 (+2.41%)

HD Home Depot
$320.13 /

+2.55 (+0.80%)

LOW Lowe's
$206.94 /

+4.87 (+2.41%)

HD Home Depot
$320.13 /

+2.55 (+0.80%)

LOW Lowe's
$206.94 /

+4.87 (+2.41%)

HD Home Depot
$320.13 /

+2.55 (+0.80%)

Syndicate
Euroseas files to sell 4.04M shares of common stock for holders  17:47
12/07/22
12/07
17:47
12/07/22
17:47
ESEA

Euroseas

$19.30 /

-0.18 (-0.92%)

 
ShowHide Related Items >><<
ESEA Euroseas
$19.30 /

-0.18 (-0.92%)

11/17/22 Univest Securities
Euroseas price target lowered to $30 from $50 at Univest Securities
10/06/22 Maxim
Euroseas price target lowered to $44 from $54 at Maxim
05/19/22 Univest Securities
Euroseas initiated with a Buy at Univest Securities
12/31/21 Maxim
Euroseas price target raised to $50 from $48 at Maxim
ESEA Euroseas
$19.30 /

-0.18 (-0.92%)

Hot Stocks
Alphabet, Oracle, Amazon and Microsoft all awarded on $9B DoD cloud contract » 17:41
12/07/22
12/07
17:41
12/07/22
17:41
GOOG

Alphabet

$95.15 /

-2.18 (-2.24%)

, GOOGL

Alphabet

$94.91 /

-2.08 (-2.14%)

, ORCL

Oracle

$78.83 /

-0.05 (-0.06%)

, AMZN

Amazon.com

$88.43 /

+0.17 (+0.19%)

, MSFT

Microsoft

$244.34 /

-0.9 (-0.37%)

Google (GOOG), Oracle…

Google (GOOG), Oracle (ORCL), Amazon (AMZN) and Microsoft (MSFT) have all been awarded a hybrid contract with a ceiling of $9B. No funds are being obligated at the time of award; funds will be obligated on individual orders as they are issued. The purpose of this contract is to provide the Department of Defense with enterprise-wide, globally available cloud services across all security domains and classification levels, from the strategic level to the tactical edge. The Joint Warfighting Cloud Capability will allow mission owners to acquire authorized commercial cloud offerings directly from the Cloud Service Providers contract awardees. Joint Warfighting Cloud Capability is a multiple award contract. The work will be performed in Reston, Virginia. The estimated completion date is June 8, 2028. Washington Headquarters Services, Arlington, Virginia, is the contracting activity.

ShowHide Related Items >><<
ORCL Oracle
$78.83 /

-0.05 (-0.06%)

MSFT Microsoft
$244.34 /

-0.9 (-0.37%)

GOOGL Alphabet
$94.91 /

-2.08 (-2.14%)

GOOG Alphabet
$95.15 /

-2.18 (-2.24%)

AMZN Amazon.com
$88.43 /

+0.17 (+0.19%)

GOOG Alphabet
$95.15 /

-2.18 (-2.24%)

11/30/22 Societe Generale
Alphabet price target lowered to $132 from $147 at Societe Generale
11/29/22 Lake Street
Google Health partnership 'significant positive' for iCAD, says Lake Street
11/15/22 Morgan Stanley
Alphabet price target lowered to $120 from $125 at Morgan Stanley
11/10/22 BofA
BofA downgrades Viant, sees things getting worse before better
GOOGL Alphabet
$94.91 /

-2.08 (-2.14%)

11/30/22 Mizuho
Alphabet price target lowered to $135 from $140 at Mizuho
11/23/22 JMP Securities
Alphabet price target lowered to $132 from $145 at JMP Securities
ORCL Oracle
$78.83 /

-0.05 (-0.06%)

12/05/22 Barclays
Oracle price target raised to $81 from $70 at Barclays
10/21/22 KeyBanc
Oracle upgraded to Overweight from Sector Weight at KeyBanc
10/21/22 KeyBanc
Oracle upgraded to Overweight from Sector Weight at KeyBanc
10/21/22 Deutsche Bank
Oracle price target raised to $120 from $110 at Deutsche Bank
AMZN Amazon.com
$88.43 /

+0.17 (+0.19%)

12/06/22 Oppenheimer
Oppenheimer remains very positive on AWS long-term despite macro weakness
12/01/22 Cowen
Amazon.com price target raised to $160 from $150 at Cowen
11/30/22 JMP Securities
JMP Securities encouraged by Amazon.com's focus on innovation
11/29/22 UBS
Affirm initiated with a Neutral at UBS
MSFT Microsoft
$244.34 /

-0.9 (-0.37%)

06:46 Today BTIG
SentinelOne price target lowered to $20 from $25 at BTIG
12/01/22 BMO Capital
Okta price target raised to $69 from $58 at BMO Capital
12/01/22 Wedbush
Activision Blizzard added to Best Ideas List at Wedbush
11/29/22 Morgan Stanley
Microsoft demand should hold up better than investors fear, says Morgan Stanley
ORCL Oracle
$78.83 /

-0.05 (-0.06%)

MSFT Microsoft
$244.34 /

-0.9 (-0.37%)

GOOG Alphabet
$95.15 /

-2.18 (-2.24%)

AMZN Amazon.com
$88.43 /

+0.17 (+0.19%)

ORCL Oracle
$78.83 /

-0.05 (-0.06%)

MSFT Microsoft
$244.34 /

-0.9 (-0.37%)

GOOG Alphabet
$95.15 /

-2.18 (-2.24%)

AMZN Amazon.com
$88.43 /

+0.17 (+0.19%)

ORCL Oracle
$78.83 /

-0.05 (-0.06%)

MSFT Microsoft
$244.34 /

-0.9 (-0.37%)

GOOG Alphabet
$95.15 /

-2.18 (-2.24%)

AMZN Amazon.com
$88.43 /

+0.17 (+0.19%)

ORCL Oracle
$78.83 /

-0.05 (-0.06%)

MSFT Microsoft
$244.34 /

-0.9 (-0.37%)

GOOGL Alphabet
$94.91 /

-2.08 (-2.14%)

GOOG Alphabet
$95.15 /

-2.18 (-2.24%)

AMZN Amazon.com
$88.43 /

+0.17 (+0.19%)

Hot Stocks
Esports Entertainment CEO Grant Johnson to leave company » 17:38
12/07/22
12/07
17:38
12/07/22
17:38
GMBL

Esports Entertainment

/

+

Esports Entertainment…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
GMBL Esports Entertainment
/

+

GMBL Esports Entertainment
/

+

10/06/22 H.C. Wainwright
Esports Entertainment downgraded to Neutral from Buy at H.C. Wainwright
09/30/22 Maxim
Maxim cuts Esports Entertainment to Hold on low visibility over direction
09/30/22 Maxim
Esports Entertainment downgraded to Hold from Buy at Maxim
05/31/22 H.C. Wainwright
Esports Entertainment price target lowered to $1.50 from $6 at H.C. Wainwright
GMBL Esports Entertainment
/

+

Periodicals
Indiana sues TikTok on security, children's access to adult content, WSJ says » 17:34
12/07/22
12/07
17:34
12/07/22
17:34
GOOG

Alphabet

$95.15 /

-2.18 (-2.24%)

, GOOGL

Alphabet

$94.91 /

-2.08 (-2.14%)

, META

Meta Platforms

$113.92 /

-0.16 (-0.14%)

, SNAP

Snap

$9.31 /

-0.135 (-1.43%)

The State of Indiana sued…

The State of Indiana sued social media platform TikTok on Wednesday, for deception of consumers with its claims on content and data security and said the platform should be barred from "allowing children to access adult content, including about sex, profanity and drugs," reported Erin Mulvaney for the Wall Street Journal. In the "first of their kind" lawsuit, Indiana cites studies that show extreme use of the platform may be linked to to "mental disorders among teenagers, including eating disorders," added the WSJ story. Other social media companies that may be impacted include YouTube (GOOG, GOOGL), Meta Platforms (META) and Snap (SNAP). Reference Link

ShowHide Related Items >><<
SNAP Snap
$9.31 /

-0.135 (-1.43%)

META Meta Platforms
$113.92 /

-0.16 (-0.14%)

GOOGL Alphabet
$94.91 /

-2.08 (-2.14%)

GOOG Alphabet
$95.15 /

-2.18 (-2.24%)

GOOG Alphabet
$95.15 /

-2.18 (-2.24%)

11/30/22 Societe Generale
Alphabet price target lowered to $132 from $147 at Societe Generale
11/29/22 Lake Street
Google Health partnership 'significant positive' for iCAD, says Lake Street
11/15/22 Morgan Stanley
Alphabet price target lowered to $120 from $125 at Morgan Stanley
11/10/22 BofA
BofA downgrades Viant, sees things getting worse before better
GOOGL Alphabet
$94.91 /

-2.08 (-2.14%)

11/30/22 Mizuho
Alphabet price target lowered to $135 from $140 at Mizuho
11/23/22 JMP Securities
Alphabet price target lowered to $132 from $145 at JMP Securities
META Meta Platforms
$113.92 /

-0.16 (-0.14%)

11/15/22 Morgan Stanley
Meta Platforms price target lowered to $100 from $105 at Morgan Stanley
11/10/22 Canaccord
Meta Platforms price target lowered to $170 from $200 at Canaccord
11/09/22 Itau BBA
Meta Platforms price target raised to $120 from $102 at Itau BBA
11/09/22 Baird
Meta layoffs represent 'significant shift in strategy,' says Baird
SNAP Snap
$9.31 /

-0.135 (-1.43%)

10/21/22 UBS
Snap price target lowered to $10 from $14 at UBS
10/21/22 Canaccord
Snap price target lowered to $12 from $16 at Canaccord
10/21/22 Susquehanna
Snap price target lowered to $8 from $11 at Susquehanna
10/21/22 Stifel
Snap price target lowered to $9 from $14 at Stifel
SNAP Snap
$9.31 /

-0.135 (-1.43%)

META Meta Platforms
$113.92 /

-0.16 (-0.14%)

GOOG Alphabet
$95.15 /

-2.18 (-2.24%)

SNAP Snap
$9.31 /

-0.135 (-1.43%)

META Meta Platforms
$113.92 /

-0.16 (-0.14%)

GOOG Alphabet
$95.15 /

-2.18 (-2.24%)

SNAP Snap
$9.31 /

-0.135 (-1.43%)

META Meta Platforms
$113.92 /

-0.16 (-0.14%)

GOOG Alphabet
$95.15 /

-2.18 (-2.24%)

SNAP Snap
$9.31 /

-0.135 (-1.43%)

META Meta Platforms
$113.92 /

-0.16 (-0.14%)

GOOGL Alphabet
$94.91 /

-2.08 (-2.14%)

GOOG Alphabet
$95.15 /

-2.18 (-2.24%)

Hot Stocks
Transocean announces $1.04B contract award for ultra-deepwater drillships » 17:34
12/07/22
12/07
17:34
12/07/22
17:34
RIG

Transocean

$3.69 /

-0.175 (-4.53%)

Transocean…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
RIG Transocean
$3.69 /

-0.175 (-4.53%)

RIG Transocean
$3.69 /

-0.175 (-4.53%)

11/18/22 Piper Sandler
Transocean price target raised to $5 from $4 at Piper Sandler
10/17/22 Susquehanna
Transocean price target lowered to $3.30 from $4.20 at Susquehanna
10/07/22 Piper Sandler
Transocean assumed with a Neutral at Piper Sandler
10/06/22 Barclays
Barclays double upgrades Transocean on better offshore drilling market
RIG Transocean
$3.69 /

-0.175 (-4.53%)

RIG Transocean
$3.69 /

-0.175 (-4.53%)

RIG Transocean
$3.69 /

-0.175 (-4.53%)

Syndicate
Better Therapeutics files to sell common stock, no amount given  17:21
12/07/22
12/07
17:21
12/07/22
17:21
BTTX

Better Therapeutics

$1.40 /

-0.06 (-4.11%)

 
ShowHide Related Items >><<
BTTX Better Therapeutics
$1.40 /

-0.06 (-4.11%)

BTTX Better Therapeutics
$1.40 /

-0.06 (-4.11%)

11/15/22 Chardan
Better Therapeutics price target lowered to $14 from $17 at Chardan
07/29/22 Chardan
Better Therapeutics price target raised to $17 from $15 at Chardan
03/16/22 Chardan
Better Therapeutics price target raised to $18 from $17 at Chardan
12/28/21
LifeSci sees 192% upside in Better Therapeutics, starts with Outperform
BTTX Better Therapeutics
$1.40 /

-0.06 (-4.11%)

Syndicate
Myomo files automatic mixed securities shelf » 17:20
12/07/22
12/07
17:20
12/07/22
17:20
MYO

Myomo

/

+

A.G.P./Alliance Global…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
MYO Myomo
/

+

MYO Myomo
/

+

11/11/22 Alliance Global Partners
Myomo price target lowered to $3.60 from $6 at Alliance Global Partners
09/28/22 Alliance Global Partners
Alliance Global Partners says CMS determination on Myomo request could come soon
07/08/22 Alliance Global Partners
Myomo price target lowered to $6.70 from $10 at Alliance Global Partners
05/12/22 Alliance Global Partners
Myomo price target lowered to $10 from $19 at Alliance Global Partners
MYO Myomo
/

+

Syndicate
SAB Biotherapeutics announces $7.9M private placement of common stock » 17:17
12/07/22
12/07
17:17
12/07/22
17:17
SABS

SAB Biotherapeutics

$1.00 /

-0.0147 (-1.46%)

SAB Biotherapeutics…

SAB Biotherapeutics announced it has entered into a securities purchase agreement for the private placement of approximately 7.3M shares of its common stock and warrants to purchase an equal number of common stock. Existing SAB investors - including T. Denny Sanford, an experienced biotech investor and healthcare philanthropist -- as well as new institutional investors participated in the private placement. Brookline Capital Markets, a division of Arcadia Securities LLC, served as the exclusive placement agent for the private placement transaction.

ShowHide Related Items >><<
SABS SAB Biotherapeutics
$1.00 /

-0.0147 (-1.46%)

SABS SAB Biotherapeutics
$1.00 /

-0.0147 (-1.46%)

11/29/22 H.C. Wainwright
SAB Biotherapeutics initiated with a Buy at H.C. Wainwright
08/11/22 Chardan
SAB Biotherapeutics price target lowered to $3 from $7 at Chardan
08/11/22 Baird
SAB Biotherapeutics price target lowered to $4 from $8 at Baird
05/13/22 Chardan
SAB Biotherapeutics price target lowered to $7 from $10 at Chardan
SABS SAB Biotherapeutics
$1.00 /

-0.0147 (-1.46%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.